NEW YORK (GenomeWeb News) – NextGen Sciences said today that it has sold its electrophoresis business to Sigma-Aldrich for an undisclosed sum.

The Ann Arbor, Mich.-based company said the deal is part of its strategic realignment plan to pare back its operations and focus on its biomarker services.

Under this agreement, Sigma-Aldrich has acquired NextGen's automated gel casting unit, the a2DEoptimizer, and its large format pre-cast gels for a cash payment and royalties based on revenues over three years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.